ATI Stock Recent News
ATI LATEST HEADLINES
ATI-1701 provides full protection against lethal tularemia in animal models after one year Company to provide update on tularemia vaccine candidate ATI-1701 and present new data on efficacy Presentation scheduled for 3:15 pm ET on October 17, 2024 HALIFAX, Nova Scotia, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that Gary Nabors, Ph.D., Chief Development Officer, and key members of Appili's scientific team, will participate at IDWeek 2024™, and present an update on the Appili biodefense program ATI-1701.
--(BUSINESS WIRE)-- #HighSchoolVoterRegistration--SEE DEMOCRACY IN ACTION: MULTIPLE ALLEGHENY COUNTY HIGH SCHOOLS CONDUCT VOTER REGISTRATION DRIVES THIS WEEK.
The latest trading day saw Allegheny Technologies (ATI) settling at $62.83, representing a -1.83% change from its previous close.
The latest trading day saw Allegheny Technologies (ATI) settling at $65.59, representing a -0.56% change from its previous close.
DALLAS , Oct. 1, 2024 /PRNewswire/ -- ATI (NYSE: ATI) has scheduled the live webcast for its third quarter 2024 earnings conference call on Tuesday, October 29, 2024, at 7:30 a.m. CT (8:30 a.m.
Allegheny Technologies (ATI) concluded the recent trading session at $65.32, signifying a -0.15% move from its prior day's close.
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Trea
The latest trading day saw Allegheny Technologies (ATI) settling at $61.77, representing a -0.69% change from its previous close.
This stock repurchase program renewal demonstrates ATI's confidence in its long-term financial performance, as well as its strong cash and liquidity position.
PITTSBURGH , Sept. 3, 2024 /PRNewswire/ -- ATI Inc. (NYSE: ATI) announced that its Board of Directors has authorized the repurchase of up to $700 million of its outstanding common stock, which the Company currently expects will support a multi-year share repurchase program.